UCLA scientists presented a next-generation CAR‑T cell platform engineered to overcome the immunosuppressive microenvironment characteristic of many solid tumors. The group described modifications that enhance CAR‑T persistence, trafficking, and resistance to local suppression—features that have limited CAR‑T efficacy outside hematologic cancers. Preclinical data suggest the engineered cells show improved infiltration and antitumor activity in multiple solid tumor models. Developers note that solid‑tumor CAR‑T therapies face delivery, safety and manufacturing hurdles; these data aim to support first‑in‑human translation plans and collaboration with clinical translational centers.